Page 5 - Roche Hemlibra Non-inhibitors - Product Monograph
P. 5
MORTALITY
Based on a recent study, there are
over 130 UAE patients with
According to the CDC, hemophilia A hemophilia, 110 of which are
affects 1 in 5,000 male births in the hemophilia A patients.
United States (US). About 400
babies are born with hemophilia A
each year (CDC. 2020).
It has been found that patients
with nonsevere hemophilia A
Use of clotting factor concentrates to
treat hemophilia A patients may elicit carry a lifelong risk for this
inhibitor formation. This is associated serious complication
(Kloosterman F et al. 2020).
with an increased burden of disease
and a higher mortality rate
(Kloosterman F et al. 2020).
Intracranial hemorrhage is one of the
major causes of fatal bleeding
(Kloosterman F et al. 2020). It
Even though nonsevere hemophilia is remains a serious issue and portrays
characterized by a milder bleeding unmet needs in the management of
phenotype, patients can still suffer nonsevere hemophilia A
from life threatening and fatal bleeds (Kloosterman F et al. 2020).
(Kloosterman F et al. 2020).
The INSIGHT study established that FVIII
inhibitor development in nonsevere
When compared to the general hemophilia A is associated with a far
population, a 3.5 fold higher more severe clinical outcome than
mortality rate is found for previously acknowledged, illustrated by
intracranial hemorrhage in the a 10 fold increase in bleeding rate and a
INSIGHT cohort (Kloosterman F 5 fold increase in mortality rate
et al. 2020). (Kloosterman F et al. 2020).
JOINT BLEEDS
The following points are true of joint bleeds:
They are
They are a major excruciatingly painful
complication of hemorrhages
hemophilia A
They cause decreased
They are experienced mobility due to the
by majority of patients pressure of blood filling
(Poon et al. 2012) the joint cavity
Historically, about 90% patients with severe hemophilia experience such chronic degenerative
changes (hemophilic arthropathy) in one to six major joints (e.g., ankles, elbows, knees) by the
second or third decade of life (Rodriguez Merchan 2010).
HEMLIBRA Monograph-Non-inhibitors | 03
®
